Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 6/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 5/20 | 1.00 |
| ▸ | PAK2 | Q13177 | 4/20 | 1.00 |
| ▸ | PAK3 | O75914 | 3/20 | 1.00 |
| ▸ | PAK4 | O96013 | 4/20 | 0.76 |
| ▸ | WEE1 | P30291 | 1/20 | 0.68 |
| ▸ | CDK4 | P11802 | 3/20 | 0.55 |
| ▸ | CCND1 | P24385 | 3/20 | 0.55 |
| ▸ | CCND2 | P30279 | 3/20 | 0.55 |
| ▸ | CCND3 | P30281 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | STK3 | Q13188 | 1/20 | 0.49 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554062 | 1.00 | PAK1 (1.00) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL14824805 | 0.94 | PAK1 (0.89) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL14681933 | 0.92 | PAK1 (0.85) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL14824801 | 0.92 | PAK1 (0.85) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL14693006 | 0.92 | PAK1 (0.84) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL1680898 | 0.91 | PAK1 (0.84) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL13554061 | 0.91 | PAK1 (0.83) | PAK1PKN1PAK2PAK3PAK4 | |
| Hydrochloric Acid SCHEMBL1680884 | 0.91 | PAK1 (0.84) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL13553594 | 0.90 | PAK1 (0.81) | PAK1PKN1PAK2PAK3PAK4 | |
| SCHEMBL14824806 | 0.89 | PAK1 (0.81) | PAK1PKN1PAK2PAK3PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | claimed |
| WO-2025096405-A1 | METHODS OF TREATING BLOOD CANCERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| CN-117295522-A | Compositions and methods for megalin inhibitors and photodynamic therapy for the treatment of cancer | 香港大学 | 2023-12-26 | — | — | CN | claimed |
| CN-114869889-B | Application of FRAX597 compound in preparation of medicines for treating Ebola virus diseases | 中国人民解放军军事科学院军事医学研究院 | 2023-07-25 | — | — | CN | claimed |
| US-11685954-B2 | Biomarkers predictive of endocrine resistance in breast cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | claimed |
| CN-114767864-B | Use of Pak3 inhibitors for the treatment of remifentanil-induced incision hyperalgesia | 天津医科大学总医院 | 2023-05-12 | — | — | CN | claimed |
| WO-2022237864-A1 | COMPOSITIONS AND METHODS OF MACROPINOCYTOSIS INHIBITORS AND PHOTODYNAMIC THERAPY TO TREAT CANCERS | THE UNIVERSITY OF HONG KONG (CN) | 2022-11-17 | — | — | WO | claimed |
| CN-114869889-A | Application of FRAX597 compound in preparation of medicine for treating Ebola virus disease | 中国人民解放军军事科学院军事医学研究院 | 2022-08-09 | — | — | CN | claimed |
| CN-114767864-A | Use of Pak3 inhibitors in the treatment of remifentanil-induced notched hyperalgesia | 天津医科大学总医院 | 2022-07-22 | — | — | CN | claimed |
| US-20220220480-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INST NAT SANTE RECH MED (FR) | 2022-07-14 | — | — | US | claimed |
| US-20220079948-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING HIV-INFECTION AND/OR A RELATED CLINICAL CONDITION THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-03-17 | — | — | US | claimed |
| EP-3956446-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-23 | — | — | EP | claimed |
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | disclosed |
| EP-4735120-A2 | CHEMICALLY INDUCED REPROGRAMMING TO REVERSE AGING | President and Fellows of Harvard College (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260034249-A1 | COMPOSITIONS AND METHODS FOR MODIFYING FERTILITY | THE BROAD INSTITUTE, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3956446-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022025827-A1 | METHOD OF STIMULATING PROLIFERATION OF A CELL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220480-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | LITAF, APAF1, CASP1 | PAK1 11/4885PKN1 1157/4885PAK2 8/4885 |
| US-20260034249-A1 | COMPOSITIONS AND METHODS FOR MODIFYING FERTILITY | PGRMC2, TAGLN2, PGRMC1 | PAK1 4815/4885PKN1 685/4885PAK2 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.